InMed Pharmaceuticals Inc. (INM) Social Stream
InMed Pharmaceuticals Inc (INM) Price Targets From Analysts
Use the tables below to see what analysts covering InMed Pharmaceuticals Inc think about its future price and what recommendations they have for investors and traders.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
INM's average price target has moved down $5.9 over the prior 14 months.
INM reports an average of 308.02% for its upside potential over the past 40 weeks.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
INM Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- To contextualize these metrics, consider that out of all US stocks, InMed Pharmaceuticals Inc's upside potential (average analyst target price relative to current price) is greater than 590.05% of them.
- INM has a greater number of analysts covering the stock than 14.13% of all US stocks.
- To contextualize these metrics, consider that out of all US stocks, InMed Pharmaceuticals Inc's average analyst price target is higher than 31.9% of them.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, InMed Pharmaceuticals Inc's variance in analysts' estimates is lower than 66.46% of them.
In the Pharmaceutical Products industry, IMRN, DRMA, and BNTC are the three stocks most similar to InMed Pharmaceuticals Inc regarding the price target and analyst recommendation information presented here.
What is the outlook for INM? Use POWR Ratings for clearer insight into price direction.